[비즈니스포스트] Hanmi Science, the holding company of Hanmi Pharmaceutical Group, and OCI Holdings (OCI), a global advanced materials company, announced group integration. With the group integration, Hanmi Group’s eldest daughters Lim Joo-hyun, president of Hanmi Science, and OCI Chairman Lee Woo-hyun will lead the group under their own representative system.
However, it appears that the company is embroiled in internal strife as Hanmi Pharmaceutical President Lim Jong-yoon (Chairman of Corey Group), the eldest son of the late Lim Seong-gi, founder of Hanmi Pharmaceutical Group, raised the issue.
“Is the management rights dispute between Lim Jong-yoon siblings intensifying?” height=”150″ src=” width=”300″ /> ▲ Hanmi Pharmaceutical Group’s eldest daughter Lim Joo-hyun, president of Hanmi Science. <한미>
According to the pharmaceutical industry on the 15th, the possibility of a management dispute between Hanmi Pharmaceutical Group and OCI Group is emerging ahead of the integration of Hanmi Pharmaceutical Group and OCI Group.
On the 12th, Hanmi Pharmaceutical Group and OCI signed an agreement on inter-group integration through in-kind investment and new stock issuance, following resolution by each company’s board of directors.
According to this contract, OCI Holdings acquired a 27.0% stake in Hanmi Science, the holding company of Hanmi Group (18.6% from old stock and in-kind investment, 8.4% from new stock issuance), and major shareholders of Hanmi Science, including Director Lim, acquired a 10.4% stake in OCI Holdings. do.
Hanmi Pharmaceutical Group appointed its eldest daughter, Lim Joo-hyun, as president in this OCI merger.
The group stated that the reason for appointing President Lim Joo-hyun was because, as the ‘Director of the Strategic Planning Office’, he is participating more substantially in the management of the company than his eldest son, President Lim Jong-yoon.
In fact, President Lim Jong-yoon does not belong to the board of directors of Hanmi Science, the holding company of Hanmi Pharmaceutical Group. Her eldest daughter, President Lim Joo-hyun, will serve as the ‘Director of the Korea-US Science Strategic Planning Office’ from July 2023, and she is focusing on the internal affairs of the Korea-US Group.
Hanmi Pharmaceutical Group said, “This integration procedure was decided unanimously by Hanmi Science board members. Although President Lim Jong-yoon is an internal director of Hanmi Pharmaceutical, he does not belong to the board of directors of Hanmi Science, the holding company.”
However, President Lim Jong-yoon has clearly stated his opposition to integration with OCI and is taking legal action.
Is the management rights dispute between Lim Jong-yoon siblings intensifying?” height=”150″ src=” width=”300″ /> ▲ Hanmi Pharmaceutical Group’s eldest son, Lim Jong-yoon, president of Hanmi Pharmaceutical.
On Saturday the 13th, President Lim Jong-yoon said through his company’s ‘Kory Group’ social networking service (SNS) account, “I have not received any form of notice or information related to the equity contract from the Korean-American side or my family,” and “I am sorry about the current situation.” “After a careful and comprehensive investigation, we will express our official position,” he said.
In addition, it is known that he will take legal action in solidarity with his younger brother, CEO Lim Jong-hoon.
According to the Financial Supervisory Service’s electronic disclosure system, President Lim Jong-yoon holds a 9.91% stake in Hanmi Science. Song Young-sook, chairman of Hanmi Pharmaceutical Group, who led the integration, and Lim Joo-hyun, president of Hanmi Science, have a stake of 11.66% and 10.2%, respectively.
The second son, Lim Jong-hoon, CEO of Hanmi Pharmaceutical, owns 10.56% of the shares. If President Lim Jong-yoon joins forces with his younger brother Lim Jong-hoon, Hanmi Science’s shareholding will exceed 20%.
Hanmi Pharmaceutical Group said, “We will continue to meet with President Lim Jong-yoon and explain the purpose and direction of this integration to ensure that this integration proceeds without a hitch.”
There is also an analysis that Hanyang Precision Chairman Shin Dong-guk holds the key to the direction of management.
Chairman Shin is the largest individual shareholder and a high school junior of the late founder Lim Seong-ki. It holds an 11.52% stake in Hanmi Science.
The prevailing view in the securities industry is that the integration of Korea-U.S. and OCI will proceed as decided.
Hi Investment & Securities said in an OCI report on the 15th, “As this share acquisition transaction was concluded through resolutions of the boards of directors of both companies, the possibility of a complete invalidation is expected to be low.” Reporter Bae Yoon-ju
2024-01-15 06:43:35
#Hanmi #Pharmaceutical #merged #OCI #facing #management #dispute #Lim #Joohyun #Lim #Jongyoon #siblings
